Clinical trial
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein…
NCT00154271 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00154271 |
|---|---|
| Title | Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) |
| Official title | Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Valsartan, Valsartan HCT |
| Enrollment | 1,677 |
| Start date | Jan 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: